Foley Partner Mark Waxman was quoted in an article titled “What impact will Obama administration have on human subjects research?” in the February 1, 2010 issue of IRB Advisor. Waxman discusses proposed changes to the health care industry under the Obama administration, stating that a possible change would be the lifting of the ban on federal funding of stem cell research and an increase in the number of stem cell trials. He adds that two bills to watch are the Fair Access to Clinical Trials act, which would strengthen a national data base of clinical trials information, and the Physician Payments Sunshine Act of 2008, which calls for transparency in physician relationships with pharmaceutical and device companies.
Related News
January 6, 2026
In the News
Kyle Faget Weighs in on Pharmaceutical Industry Legal Battles
Foley & Lardner LLP partner Kyle Faget shared insight with Law360 on major legal topics affecting the pharmaceutical industry.
January 2, 2026
In the News
Judith Waltz Shares Insights on Key Health Law Developments on AHLA Podcast
Foley & Lardner LLP partner Judith Waltz hosted the American Health Law Association's Speaking of Health Law podcast to discuss major health law developments from 2025 and offer insights on trends expected in 2026.
January 2, 2026
In the News
Rajiv Dharnidharka Examines Trade Secret Litigation Trends
Foley & Lardner LLP partner Rajiv Dharnidharka commented on anticipated developments in trade secret law this year in the Law360 article, “Trade Secret Trends To Watch In 2026.”